Loss of Slc35a2 alters development of the mouse cerebral cortex.

CRISPR Cerebral cortex Cortical dysplasia Glycosylation Short-hairpin RNA

Journal

Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130

Informations de publication

Date de publication:
21 Jun 2024
Historique:
received: 04 03 2024
revised: 17 06 2024
accepted: 19 06 2024
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 23 6 2024
Statut: aheadofprint

Résumé

Brain somatic variants in SLC35A2, an intracellular UDP-galactose transporter, are commonly identified mutations associated with drug-resistant neocortical epilepsy and developmental brain malformations, including focal cortical dysplasia type I and mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). However, the causal effects of altered SLC35A2 function on cortical development remain untested. We hypothesized that focal Slc35a2 knockout (KO) or knockdown (KD) in the developing mouse cortex would disrupt cortical development and change network excitability. Through two independent studies, we used in utero electroporation (IUE) to introduce CRISPR/Cas9/targeted guide RNAs or short-hairpin RNAs into the embryonic mouse brain at day 14.5-15.5 to achieve Slc35a2 KO or KD, respectively, from neural precursor cells. Slc35a2 KO or KD caused disrupted radial migration of electroporated neurons evidenced by heterotopic cells located in lower cortical layers and in the sub-cortical white matter. Slc35a2 KO in neurons did not induce changes in oligodendrocyte number, importantly suggesting that the oligodendroglial hyperplasia observed in MOGHE originates from distinct cell autonomous effects of Slc35a2 mutations. Adult KO mice were implanted with EEG electrodes for 72-hour continuous recording. Spontaneous seizures were not observed in focal Slc35a2 KO mice, but there was reduced seizure threshold following pentylenetetrazol injection. Here we demonstrate that focal Slc35a2 KO or KD in vivo disrupts corticogenesis through altered neuronal migration and that KO leads to reduced seizure threshold. Together these results demonstrate a direct causal role for SLC35A2 in cortical development.

Identifiants

pubmed: 38909838
pii: S0304-3940(24)00259-3
doi: 10.1016/j.neulet.2024.137881
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

137881

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Soad Elziny (S)

Dept. of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.

Sahibjot Sran (S)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States.

Hyojung Yoon (H)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States.

Rachel R Corrigan (RR)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States.

John Page (J)

Dept. of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.

Amanda Ringland (A)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States.

Anna Lanier (A)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States.

Sara Lapidus (S)

Dept. of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.

James Foreman (J)

Dept. of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.

Erin L Heinzen (EL)

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy and Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Philip Iffland (P)

Dept. of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.

Peter B Crino (PB)

Dept. of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.

Tracy A Bedrosian (TA)

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States; Dept. of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States. Electronic address: tracy.bedrosian@nationwidechildrens.org.

Classifications MeSH